On July 2, 2025, CMS issued an NCD that covers FDA approved Transcatheter Edge-to-Edge Repair for Tricuspid Valve Regurgitation (T-TEER) for the treatment of symptomatic tricuspid regurgitation (TR) under Coverage with Evidence Development (CED), when furnished in accordance with the coverage criteria specified in the NCD. The complete NCD decision memorandum is available on our website.
Below is a list of studies that have been determined to meet the requirements for coverage under CED.
Study Title: TRIClip CoverAge with Evidence Development (CED) Real-World Evidence (RWE) Study (TRICARE)
Sponsor: Abbott
Clinicaltrials.gov number: NCT06920745
CMS Approval Date: 07/08/2025
Page Last Modified:
07/09/2025 03:05 PM